Boardroom Alpha
Boardroom Alpha
SXI · Current Report (Form 8-K) · Filed November 10, 2025

Standex International Corp — Current Report (Form 8-K)

Form
8-K
Filed
November 10, 2025
Period
Nov 5, 2025
Ticker
SXI
Accession
0001437749-25-034131
Boardroom Alpha · Filing insights

Board accepts CHRO Annemarie Bell's resignation. Michelle Newbury appointed CHRO effective November 10, 2025.

About Standex International Corp
Market cap
$3.3B
1Y TSR
+51.6%
3Y TSR
+29.0%
Board grade
B+
Sector
Industrials
CEO
David A Dunbar
Last annual meeting: Oct 20, 2026 · View full Standex International Corp profile →
sxi20251110_8k.htm
 
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
 

 
FORM 8-K
 
Current Report
Pursuant to Section 13 or 15(d) of
the Securities Exchange Act of 1934
 
Date of Report (Date of earliest event reported): November 5, 2025
 
 
STANDEX INTERNATIONAL CORPORATION
(Exact name of registrant as specified in its charter)
 

 
Delaware
 
1-7233
 
31-0596149
(State or other jurisdiction of
incorporation or organization)
 
(Commission
File Number)
 
(IRS Employer
Identification No.)
 
23 Keewaydin Drive, Salem, New Hampshire
 
03079
(Address of principal executive offices)
  (Zip Code)
 
Registrants telephone number, including area code: (603) 893-9701
 
Not applicable
(Former name or former address, if changed since last report)
 
Securities registered pursuant to Section 12(b) of the Act:
 
Title of each class
Trading Symbol(s)
Name of each exchange on which registered
Common Stock, Par Value $1.50 Per Share
SXI
New York Stock Exchange
 
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
 
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
 
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
 
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
 
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
 
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 or Rule 12b-2 of the Securities Exchange Act of 1934.
 
Emerging growth company         ☐
 
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
 
 

 
Standex International Corporation
 
 
ITEM 5.02 DEPARTING DIRECTORS OR CERTAIN OFFICERS; ELECTION OF DIRECTORS; APPOINTMENT OF CERTAIN OFFICERS; COMPENSATORY ARRANGEMENTS TO CERTAIN OFFICERS
 
(b)    On November 5, 2025, the Board of Directors accepted the resignation, effective November 10, 2025, of Annemarie Bell, Chief Human Resources Officer for the Company and a named executive officer, from her position as an executive officer of the Corporation. Ms. Bell will be transitioning into a role focusing on executive coaching and leadership development, addressing a significant organizational need at the Company. This change will support Ms. Bell in focusing on her well-being as she navigates a significant health challenge, while remaining engaged in contributing meaningfully to the Company.
On November 5, 2025, the Board of Directors also appointed, effective November 10, 2025, Michelle Newbury to the role of Chief Human Resources Officer to fill the vacancy created by Ms. Bell’s transition. Ms. Newbury, age 46, will oversee the Company’s global human resources strategy, including talent management, organizational development, compensation and benefits, diversity and inclusion, and employee engagement initiatives. Ms. Newbury has more than 20 years of human resources leadership experience, with a strong track record of driving cultural transformation, leadership development, and operational excellence. Prior to joining the Company, she served as Vice President of Human Resources at Cornerstone Building Bands, Vice President of Human Resources at Kymera International, and Senior Director of Human Resources at Pentair, where she was responsible for insightful global leadership in both the private and public sectors.
 
SIGNATURE
 
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.
 
STANDEX INTERNATIONAL CORPORATION
(Registrant)
 
 
/s/ Ademir Sarcevic

Ademir Sarcevic
Chief Financial Officer
 
Date: November 10, 2025
 
Signing on behalf of the registrant and as principal financial officer
 
 
From this filing to the file

Every SEC filing, parsed structured.

Boardroom Alpha indexes every 8-K, 10-K, 10-Q, and proxy back to 2000 — vote tabulations, comp tables, red flags, insider transactions, all queryable the day they hit EDGAR.

Independent — issuer-pays-free, ideology-free, U.S.-owned.

More filings

Other filings from Standex International Corp (SXI)

Reference

Frequently asked questions

When did Standex International Corp file this 8-K?
Standex International Corp (SXI) filed this Current Report (Form 8-K) with the SEC on November 10, 2025. The accession number assigned by EDGAR is 0001437749-25-034131.
What does an 8-K disclose?
Form 8-K is the SEC's current-report form, used to disclose material events between periodic reports (10-K / 10-Q). Triggers include CEO/CFO departures, acquisitions, bankruptcies, earnings releases, auditor changes, changes in fiscal year, and amendments to corporate governance. Each 8-K is keyed to one or more Item numbers (1.01 through 9.01).
What is the key takeaway from this filing?
Board accepts CHRO Annemarie Bell's resignation. Michelle Newbury appointed CHRO effective November 10, 2025. This is Boardroom Alpha's one-line summary of the current report; see the full filing text above for the formal disclosure.
What Item codes does an 8-K cover?
An 8-K's Item codes (1.01 through 9.01) specify what kind of event is being disclosed — e.g. Item 1.01 for entering a material agreement, Item 5.02 for departure/election of directors and executive officers, Item 8.01 for other events. The Item codes for this 8-K appear in the filing text above.
Where can I find Standex International Corp's prior current reports on EDGAR?
The SEC EDGAR browser lists every 8-K Standex International Corp has filed under CIK 310354, sortable by date. Use the "View on SEC EDGAR" link in the page header, or browse directly via https://www.sec.gov/cgi-bin/browse-edgar.
Disclaimer

The opinions and information contained herein have been obtained or derived from sources believed to be reliable, but Boardroom Alpha cannot guarantee its accuracy and completeness, and that of the opinions based thereon.

This report contains opinions and is provided for informational purposes only – it does not constitute investment, legal or tax advice. You should not rely solely upon the research herein for purposes of transacting securities or other investments, and you are encouraged to conduct your own research and due diligence, and to seek the advice of a qualified securities professional before you make any investment.

None of the information contained in this report constitutes, or is intended to constitute a recommendation by Boardroom Alpha of any particular security or trading strategy or a determination by Boardroom Alpha that any security or trading strategy is suitable for any specific person. To the extent any of the information contained herein may be deemed to be investment advice, such information is impersonal and not tailored to the investment needs of any specific person.

No representation or warranty, expressed or implied, is made on behalf of Boardroom Alpha as to the accuracy or completeness of the information contained herein. Boardroom Alpha does not accept any liability for any direct, indirect or consequential loss or damage suffered by any person as a result of relying on all or any part of this research and any liability is expressly disclaimed.

Full disclaimer